Inhibitor/Activator
| Cat.No. | Name | Information |
|---|---|---|
| M9083 | Disitertide | Disitertide is a TGF-β1 inhibitor. |
| M4863 | Kartogenin | Kartogenin is an activator of the smad4/smad5 pathway, and promotes the selective differentiation of multipotent mesenchymal stem cells into chondrocytes. |
| M2328 | Pirfenidone | Pirfenidone inhibits TGF-β bioactivity by affecting TGF-β2 mRNA expression and processing of pro-TGF-β in CCL-64 cells. Pirfenidone (AMR69) attenuates CCL2 and CCL12 production in fibrocyte cells. |
| M39853 | Dalbergioidin | Dalbergioidin, a well-known anthocyanin, ameliorates doxorubicin-induced renal fibrosis by suppressing the TGF-β signal pathway. Dalbergioidin exhibits tyrosinase inhibitory activity with an IC50 of 20 mM. |
| M25307 | Fresolimumab | Fresolimumab (GC1008) is a high-affinity fully human monoclonal antibody that neutralizes the active form of human TGFβ1, TGFβ2, and TGFβ3. Fresolimumab can be used for the research of cancer and fibrotic diseases . |
| M25202 | Metelimumab | Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that can selectively neutralize TGFβ1. |
| M25098 | Ponsegromab | Ponsegromab (PF 06946860) is a potent and selective humanized anti-GDF15 antibody inhibitor with anti-cachexia activity. Ponsegromab binds to GDF15 and prevents the binding of GDF15 to GFRAL, thereby blocking GDF15/GFRAL-mediated signaling. Ponsegromab can be used in the research of cancers. |
| M24625 | Bimagrumab | Bimagrumab (BYM338) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness. |
| M24570 | Dalantercept | Dalantercept (ACE-041) is an activin receptor like kinase 1 (ALK1) inhibitor, a ligand trap for bone morphogenetic proteins (BMP) 9 and BMP 10. Dalantercept reduces tumor angiogenesis and delays tumor growth by binding to BMP 9 and BMP 10. As an anti angiogenic agent, Dalantercept has potential applications in persistent or recurrent ovarian cancer, renal cell carcinoma (RCC), and related malignant tumors. |
| M24561 | Ramatercept | Ramatercept is a soluble ActRIIB receptor and can be used as a soluble activin receptor 2 (ACVR2) antagonist. Ramatercept inhibits the signal pathway of muscle growth inhibition and has potential application in muscle atrophy. |
| M24529 | Sotatercept | Sotatercept (ACE-011; MK-7962) is a first-in-class activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions. |
| M20256 | TGFβ-IN-5 | TGFβ-IN-5 is a TGFβ inhibitor useful for the study of fibroproliferative diseases associated with TGF-β signaling. |
| M14946 | LSKL, Inhibitor of Thrombospondin (TSP-1) TFA | LSKL, Inhibitor of Thrombospondin (TSP-1) TFA is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. |
| M14930 | Disitertide diammonium | Disitertide (P144) diammonium is a polypeptide inhibitor of transforming growth factor TGFβ1, specifically blocking its interaction with the receptor. Disitertide diammonium was also an inhibitor of PI3K and an inducer of apoptosis. |
| M10712 | BIO-013077-01 | BIO-013077-01 is a Pyrazole inhibitor of TGF-β. |
| M10455 | BMP signaling agonist sb4 | BMP signaling agonist sb4 (SB-4) is a potent benzoxazole bone morphogenetic protein 4 (BMP4) signaling agonist with a EC50 value of 74 nM. BMP signaling agonist sb4 activates BMP signaling by stabilizing intracellular p-SMAD-1/5/9. |
| M9713 | SJ000291942 | SJ000291942 is a bone morphogenic protein (BMP) signaling activator. |
| M9522 | SRI-011381 | SRI-011381 is an agonist of the TGF-beta signaling pathway for treatment of Alzheimer's disease. |
| M9223 | R-268712 | R-268712 is a potent and selective inhibitor of ALK5 with an IC50 of 2.5nM, an approximately 5000-fold more selectivity for ALK5 than p38 mitogen-activated protein kinase (MAPK). |
| M9088 | SRI-011381 hydrochloride | SRI-011381 hydrochloride is an agonist of the TGF-beta signaling pathway for treatment of Alzheimer's disease. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
